Top news of the week: 13.07.2022.
Beyond Biotech podcast 4: CorePath, Rensselaer, Versameb
This week’s guests: Helen Zha, Rensselaer Polytechnic Institute; Versameb's Klaas Zuideveld; and Aamir Ehsan and Celina Villa from CorePath.
Preventing the next pandemic: Supporting early-stage R&D
In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the ...
Research Roundup: a Potential Vaccine for ALS & More
Researchers and biotech companies are working on developing vaccines and therapies for cancer, ALS, COVID-19, obesity and psoriasis. Here's a look at just some of them.
Innoviva Snags Lucrative La Jolla Portfolio in $149M Deal
Innoviva Inc. and La Jolla Pharmaceutical Company announced Monday that they had entered into a $149-million merger agreement.
Pliant and Annexon Seek and Secure Funds for Pulmonary Fibrosis, Autoimmune Treatments
Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.
Analyst: Value of Accelerated Approvals Exceeds Minimal Medicaid Costs
Emory University's Ken Thorpe told BioSpace that the average Medicaid spending on drugs approved under the accelerated pathway in relation to total Medicaid spending is.2%.
Spatial and NGS Dominate Proceedings at AGBT
The annual meeting in Florida delivered technological advances that generated lots of hype, some healthy skepticism, and genuine excitement.
Myrtelle Presents Latest Positive Data in Canavan Treatment Space
Weeks after BridgeBio presented positive biomarker data in Canavan Disease, gene therapy company Myrtelle added its own data to the emerging research space.